Convergent Genomics Home
  • About Us
  • Our Products
  • Our Science
  • Clinical Expertise
  • Newsroom
    • Press Releases
    • Media Resources
    • Featured Content
  • Contact

FEATURED CONTENT

NEW STUDY SHOWS UROAMP CAN DETECT BLADDER CANCER NOT FOUND BY CYSTOSCOPY OR URINE CYTOLOGY

Aug 22, 2023

read more

Test Featured 3

Jul 24, 2023

read more

Test Featured 2

Jul 24, 2023

read more

Test Featured

Jul 24, 2023

read more

Genomic Urine Test Detects Bladder Cancer from DNA Up to 12 Years Before Clinical Signs and Symptoms Appear

Apr 27, 2023

read more

New Studies on Convergent Genomics’ Urine Test for Bladder Cancer to be Presented at 2023 American Urological Association (AUA) Annual Meeting

Apr 25, 2023

read more

Contact us
425 Eccles Ave, South San Francisco, CA 94080
info@convergentgenomics.com
415-839-0077




Privacy Policy

Financial Conflict of
Interest Policy

References

CA: CDF-90003755     |      CLIA # 05D2220749     |      CAP Accredited # 9512563

The UroAmp test has been developed, its performance characteristics determined, and validated by our CLIA-certified and CAP-accredited laboratory, which performs the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.